Three US senators sent a letter to the HHS Office of Inspector General with questions about TrumpRx, the structure of which has not yet been detailed.[1] TrumpRx is a federal portal for direct-to-consumer drug sales from manufacturers at most-favored-nation (MFN) prices, announced on September 30, 2025, with a planned launch in January 2026.[1][3][4][5] Participating companies are Pfizer, AstraZeneca, Merck, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead Sciences, GSK, Novartis and Sanofi, a total of 14 out of 17 approached.[1][3] Manufacturers are reducing the prices of selected drugs when purchased through TrumpRx, such as Amgen's Repatha from $573 to $239, GSK's Advair Diskus from $265 to $89, Merck's Januvia from $330 to $100, Novartis' Mayzent from $9987 to $1137, and Sanofi's Plavix from $756 to $16.[6] Sanofi will offer insulin products for $35 a month and weight loss drugs from Novo Nordisk and Eli Lilly for about $350 a month, trending to $245 within two years.[1][6] The agreements also include investments in US manufacturing of at least $150 billion and donations of active pharmaceutical ingredients to the SAPIR reserve.[6] The platform will enable purchasing without insurance and contribute to savings for Medicaid.[3][5]